Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.

No definition available.

Name:	pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Part of Acquisition Recognized

+ References

No definition available.

+ Details

Name:	pcrx_CollaborativeArrangementPartOfAcquisitionRecognized
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Upfront Payment

+ References

No definition available.

+ Details

Name:	pcrx_CollaborativeArrangementUpfrontPayment
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermPurchaseCommitmentLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.

+ References

No definition available.

+ Details

Name:	us-gaap_PurchaseObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount expected to be recognized in earnings for the specified restructuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(d))
-URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

+ Details

Name:	us-gaap_RestructuringAndRelatedCostExpectedCost1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

+ Details

Name:	us-gaap_RestructuringCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=pcrx_HongKongPharmaTainuoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pcrx_MarketingSponsorshipsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pcrx_FortisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pcrx_GeneQuineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Oct. 31, 2020	Feb. 28, 2017	Dec. 31, 2020	Jan. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Hong Kong Pharma Tainuo Ltd.
Long-term Purchase Commitment [Line Items]
Collaborative arrangement, upfront payment			$ 10.0
Achievement of Development and Commercial Milestones \| Hong Kong Pharma Tainuo Ltd.
Long-term Purchase Commitment [Line Items]
Collaborative arrangement, milestone payments to be received						$ 32.5
Collaborative arrangement, part of acquisition recognized						13.0
Achievement of Development and Commercial Milestones \| Hong Kong Pharma Tainuo Ltd. \| Subsequent Event
Long-term Purchase Commitment [Line Items]
Collaborative arrangement, part of acquisition recognized				$ 13.0
Service
Long-term Purchase Commitment [Line Items]
Purchase obligation						73.3
Raw Materials
Long-term Purchase Commitment [Line Items]
Purchase obligation						$ 5.2
Marketing Sponsorships \| Subsequent Event
Long-term Purchase Commitment [Line Items]
Purchase obligation					$ 2.8
Fortis
Long-term Purchase Commitment [Line Items]
Loss contingency, damages sought	$ 30.0
GeneQuine \| Flexion \| Achievement of Development and Regulatory Milestones
Long-term Purchase Commitment [Line Items]
Collaborative arrangement, milestone payments to be received		$ 56.0
Initiation of restructuring milestone cost		4.5
Development and global regulatory approval milestone payments		$ 51.5